Sign in Subscribe
Legislative bills

Senate Labor, Health and Human Services Appropriations Bill: A Mixed Bag for Infectious Diseases Research and Preparedness

Strategic Insights

— 2 min read

The Senate FY 2026 Labor, Health and Human Services appropriations bill provides level funding with FY 2025 to maintain some key domestic and global infectious diseases programs, including the Centers for Disease Control and Prevention's Antibiotic Resistance Solutions Initiative and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. However, the bill does not provide funding for the Bio-Preparedness Workforce Pilot Program at the Health Resources and Services Administration, a bipartisan effort to close growing ID workforce gaps that endanger patient care, public health, and preparedness.

Key Takeaways:

  • The National Institutes of Health will receive $47.201 billion in overall funding, a $400 million increase over FY 2025, with a $40 million increase over FY 2025 in overall funding.
  • The Centers for Disease Control and Prevention will receive $9.150 billion in overall funding, a $50 million decrease from FY 2025 funding.
  • The bill provides level funding for key programs, including the CDC's Antibiotic Resistance Solutions Initiative, NIAID at NIH, the Biomedical Advanced Research and Development Authority, and the Center for Global Health at NIH.
  • The Bio-Preparedness Workforce Pilot Program at the Health Resources and Services Administration did not receive funding, despite being a bipartisan effort to close growing ID workforce gaps.
  • IDSA urges Congress to provide sufficient funding in FY 2026 for ID programs, citing the importance of maintaining some key domestic and global infectious diseases programs.

Statistics:

  • $47.201 billion: Overall funding for the National Institutes of Health in FY 2026, a $400 million increase over FY 2025.
  • $9.150 billion: Overall funding for the Centers for Disease Control and Prevention in FY 2026, a $50 million decrease from FY 2025 funding.
  • $197 million: Funding for CDC's Antibiotic Resistance Solutions Initiative in FY 2026, level with FY 2025.
  • $6.592 billion: Funding for NIAID at NIH in FY 2026, a $30 million increase over FY 2025.
  • $565 million: Funding for antimicrobial resistance research at NIAID, level with FY 2025.
  • $1.015 billion: Funding for the Biomedical Advanced Research and Development Authority in FY 2026, a $40 million increase over FY 2025.
  • $692.843 million: Funding for the Center for Global Health in FY 2026, level with FY 2025.
  • $24 million: Funding for the National Healthcare Safety Network at CDC in FY 2026, level funding.
  • $40 million: Funding for the Advanced Molecular Detection initiative at CDC in FY 2026, level funding.
  • $23 million: Funding for infectious diseases and opioid activities at CDC in FY 2026, level funding.
  • $95.162 million: Funding for NIH's Fogarty International Center in FY 2026, level funding.
  • $682 million: Funding for CDC's Immunizations Program in FY 2026, level with FY 2025.

Sources:

  • Infectious Diseases Society of America
  • Press Release: Infectious Diseases Society of America
  • Senate Labor, Health and Human Services appropriations bill ( FY 2026)

Read more